We examined several well-known clinical predictors of rectal cancer treatment response, including CEA, Hb, white blood cell (WBC) count, neutrophil/lymphocyte ratio (N/L ratio), and platelet/lymphocyte ratio (P/L ratio). This evidence concerns the gene GSTM1 and rectal cancer.